Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01429103 · ClinicalTrials.gov registry record
Hormones and Cognition in the Menopausal Transition
A clinical trial of Age-associated Memory Impairment and Alteration of Cognitive Function, sponsored by University of Rochester.
- Completed
- Registry status
- 117
- Enrollment target
- 1
- Study location
NCT01429103: Completed study of Age-associated Memory Impairment and Alteration of Cognitive Function, sponsored by University of Rochester.
NCT01429103 is a study of Age-associated Memory Impairment and Alteration of Cognitive Function that has completed, run by University of Rochester. The registered enrollment target is 117 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01429103, a study of Age-associated Memory Impairment and Alteration of Cognitive Function, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- 117 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if the menopausal transition is associated with subjective and objective cognitive declines that ameliorate in menopause. The investigators hypothesize that perimenopause is associated with both subjective memory complaints and objective declines in attentionally mediated cognitive tasks. The investigators also hypothesize that this is time-limited. The investigators predict that as women transition from early perimenopause to late perimenopause their performance on attentionally mediated and verbal memory tasks will decline, and that as they transition from late perimenopause to menopause, their performance will improve.
Conditions Studied
Study Locations (1)
New York
- University of Rochester Clinical Research Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2011-05 |
| Est. Completion | 2016-11 |
What the finished NCT01429103 record still lists
NCT01429103 is an observational study that tracks outcomes without assigning an intervention. The registered 117 participants enrollment target is mid-sized for trials with a published cap.
The record links to 2 conditions, with Age-associated Memory Impairment appearing as the primary indexed condition, and to 0 interventions.
NCT01429103 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01429103 about?
NCT01429103 is a clinical study titled "Hormones and Cognition in the Menopausal Transition". The purpose of this study is to determine if the menopausal transition is associated with subjective and objective cognitive declines that ameliorate in menopause. The investigators hypothesize that perimenopause is associated with both subjective memory complaints and objective declines in attentio...
What is the current status of trial NCT01429103?
This trial is currently completed. The enrollment target is 117 participants. The study started on 2011-05. Estimated completion is 2016-11.
What conditions does trial NCT01429103 study?
This clinical trial studies the following conditions: Age-associated Memory Impairment, Alteration of Cognitive Function.
Who is sponsoring clinical trial NCT01429103?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01429103 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03539822 · 117 participants · Phase 1
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- NCT03786692 · 117 participants · Phase 2
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
- NCT04479696 · 117 participants · NA
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
- NCT04940585 · 117 participants · NA
ROSE in Sunset Park
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia